FDA Approves Abbott RealTime HCV and HBV Assays to Run on m2000

The FDA has signed off on the expansion of Abbott’s RealTime HCV and RealTime HBV assays to run on the new mPlus system. The system allows even small laboratories to perform diagnostic tests to identify and monitor infectious diseases.  

The mPlus system offers advantages over its predecessor, allowing labs to process samples at short intervals instead of waiting to batch them into larger groups and enabling faster response time. The system also optimizes reagent use for added cost savings and has a new automatic inventory feature. A recent software upgrade to version 7.0 offers automatic downloads of test orders from the laboratory Information system using a bidirectional interface.